Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaZa Study: Zanubrutinib in Primary Cold Agglutinin Disease
NCT06067048Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Jul 2024
- Primary completion
- Feb 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in cold agglutinin disease (CAD), sponsored by HOVON. Primary endpoint: Cold Agglutinin Disease Objective Response Rate at 1 year. Started Jul 2024; status: active, not recruiting.
02
Drugs
zanubrutinib
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on NCT06067048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06067048.